back to markets
SciencevaccinePhase 2closes in 235d 21h
Will an Andes/HPS vaccine candidate enter Phase 2 trials in 2026?
Hantavax (Hantaan/Seoul) is not effective against Andes. Tracks any DNA, mRNA, or VLP candidate registered on a public trial registry.
YES
41¢
NO
59¢
VOLUME · 24H
—
LIQUIDITY
—
TRADERS · 24H
—
TRADES · 24H
—
implied probability · last 30d
no data
Recent trades
no flow yet
Top holders
YES
—
NO
—
Resolution rules
Resolves YES if any candidate explicitly listed against Andes/SNV/HPS reaches Phase 2 status on ClinicalTrials.gov or EU CTR before 2026-12-31.
Settlement protocol
On settlement the oracle attaches a signed snapshot of each source URL plus a SHA-256 hash of the page content captured at resolution time. Disputes have a 7-day arbitration window.
cited: ClinicalTrials.gov + EU CTR
Resolution sources · 2
Registry·JSON API·daily
ClinicalTrials.gov
Primary
v2 API returns JSON. Resolves the vaccine-Phase-2 market. Filter `statusModule.overallStatus` and `phase`.
Registry·HTML scrape·daily
EU Clinical Trials Register
Primary
No JSON API; scrape result table.
ETL workers poll these feeds and merge into the resolution oracle.full registry
Related markets
Sciencecloses 235d 21h
Will WHO formally acknowledge sustained human-to-human Andes transmission in 2026?
implied probability
11%
warming up
YES
11¢
NO
89¢
awaiting first trade
Sciencecloses 235d 21h
Will WHO assign a Greek-letter (or successor scheme) variant name to a hantavirus lineage in 2026?
implied probability
8%
warming up
YES
8¢
NO
92¢
awaiting first trade
Sciencecloses 235d 21h
Will any regulator grant emergency authorization to a hantavirus vaccine in 2026?
implied probability
5%
warming up
YES
5¢
NO
95¢
awaiting first trade